Bohui Innovation (300318.SZ) subsidiary Ren Blood Factor VIII obtains drug registration certificate.

Zhtng cijng APP news, Bohui Innovation (300318.SZ) announced that its controlling subsidiary, Bohui Biopharmaceuticals (Hebei) Co., Ltd. (hereinafter referred to as "Hebei Bohui"), recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the drug human coagulation factor VIII developed by Hebei Bohui. This product has a corrective effect on coagulation dysfunction caused by lack of human coagulation factor VIII, mainly used for the prevention and treatment of hemophilia A and bleeding symptoms caused by acquired factor VIII deficiency, as well as surgical bleeding treatment for such patients.